Stocks News

LAST PRICE
17.3300
TODAY'S CHANGE (%)
Trending Up0.3100 (1.8214%)

Bid / Lots
15.0000/ 1
Ask / Lots
21.0000/ 3
Open / Previous Close
17.0000 / 17.0200
Day Range
Low 16.6100
High 17.5900
52 Week Range
Low 11.6650
High 42.6000
Volume
423,327
above average

Search Criteria

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Company	Country	Symbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

Nov 8, 2024
- DJ Cartesian Therapeutics Is Maintained at Buy by HC Wainwright & Co., from 2:26PM ET on Friday Nov 08, 2024 by Dow Jones
  2:26PM ET on Friday Nov 08, 2024 by Dow Jones
  Companies Mentioned: RNAC
  
  Ratings actions from Benzinga: https://www.benzinga.com/quote/RNAC/analyst-ratings
  
  (END) Dow Jones Newswires
  
  November 08, 2024 14:26 ET (19:26 GMT)
- Cartesian Therapeutics Announces New Employment Inducement Grants, from 7:05AM ET on Friday Nov 08, 2024 by Dow Jones
  7:05AM ET on Friday Nov 08, 2024 by Dow Jones
  Companies Mentioned: RNAC
  
  Cartesian Therapeutics Announces New Employment Inducement Grants
  
  FREDERICK, Md., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the "Company"), a clinical-stage biotechnology company pioneering mRNA cell therapies for the treatment of autoimmune diseases, today announced the granting of inducement awards to two new employees. On November 4, 2024, the Company issued to these employees options to purchase an aggregate of 4,854 shares of the Company's common stock with an exercise price of $19.11, the closing trading price of the Company's common stock on the Nasdaq Global Market on the date of grant. The options were granted pursuant to the Company's Amended and Restated 2018 Employment Inducement Incentive Award Plan and were approved by the Company's board of directors. The option vests as to 25% on November 4, 2025, and then in three equal annual installments thereafter such that the options will be fully vested on November 4, 2028. The options have a ten-year term. The options were granted under Rule 5635(c)(4) of the Nasdaq Listing Rules as an inducement material to the employees' entry into employment with the Company.
- DJ Cartesian Therapeutics Price Target Maintained With a $41.00/Share by Needham, from 5:01AM ET on Friday Nov 08, 2024 by Dow Jones
  5:01AM ET on Friday Nov 08, 2024 by Dow Jones
  Companies Mentioned: RNAC
  
  Ratings actions from Benzinga: https://www.benzinga.com/quote/RNAC/analyst-ratings
  
  (END) Dow Jones Newswires
  
  November 08, 2024 05:01 ET (10:01 GMT)
Nov 7, 2024
- -- Earnings Flash (RNAC) CARTESIAN THERAPEUTICS Posts Q3 Revenue $387,000, from 7:10AM ET on Thursday Nov 07, 2024 by MT Newswires
  7:10AM ET on Thursday Nov 07, 2024 by MT Newswires
  Companies Mentioned: RNAC
  07:10 AM EST, 11/07/2024 (MT Newswires) -- ...
- Press Release: Cartesian Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update, from 7:00AM ET on Thursday Nov 07, 2024 by Dow Jones
  7:00AM ET on Thursday Nov 07, 2024 by Dow Jones
  Companies Mentioned: RNAC

Yesterday
- DJ Taysha Gene Therapies Is Maintained at Buy by Canaccord Genuity, from 23 hours ago by Dow Jones
  23 hours ago by Dow Jones
  Companies Mentioned: TSHA
Nov 14, 2024
- DJ 4D Molecular Therapeutics Is Maintained at Buy by Chardan Capital, from 4:54PM ET on Thursday Nov 14, 2024 by Dow Jones
  4:54PM ET on Thursday Nov 14, 2024 by Dow Jones
  Companies Mentioned: FDMT
- DJ Taysha Gene Therapies Price Target Maintained With a $6.00/Share by Needham, from 1:54PM ET on Thursday Nov 14, 2024 by Dow Jones
  1:54PM ET on Thursday Nov 14, 2024 by Dow Jones
  Companies Mentioned: TSHA
- DJ 4D Molecular Therapeutics Price Target Maintained With a $36.00/Share by HC Wainwright & Co., from 1:41PM ET on Thursday Nov 14, 2024 by Dow Jones
  1:41PM ET on Thursday Nov 14, 2024 by Dow Jones
  Companies Mentioned: FDMT
- DJ 4D Molecular Therapeutics Is Maintained at Outperform by RBC Capital, from 12:04PM ET on Thursday Nov 14, 2024 by Dow Jones
  12:04PM ET on Thursday Nov 14, 2024 by Dow Jones
  Companies Mentioned: FDMT
- DJ Taysha Gene Therapies Price Target Maintained With a $7.00/Share by Cantor Fitzgerald, from 9:11AM ET on Thursday Nov 14, 2024 by Dow Jones
  9:11AM ET on Thursday Nov 14, 2024 by Dow Jones
  Companies Mentioned: TSHA
- 4DMT to Participate in Upcoming Investor Conferences and Ophthalmology Innovation Summit XIV, from 8:00AM ET on Thursday Nov 14, 2024 by Dow Jones
  8:00AM ET on Thursday Nov 14, 2024 by Dow Jones
  Companies Mentioned: FDMT
- RBC Trims Price Target on 4D Molecular Therapeutics to $39 From $40, Keeps Outperform, Speculative Risk, from 6:59AM ET on Thursday Nov 14, 2024 by MT Newswires
  6:59AM ET on Thursday Nov 14, 2024 by MT Newswires
  Companies Mentioned: FDMT
Nov 13, 2024
- -- Earnings Flash (TSHA) TAYSHA GENE THERAPIES Posts Q3 Revenue $1.79M, from 4:26PM ET on Wednesday Nov 13, 2024 by MT Newswires
  4:26PM ET on Wednesday Nov 13, 2024 by MT Newswires
  Companies Mentioned: TSHA
- 4DMT Reports Third Quarter 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones, from 4:05PM ET on Wednesday Nov 13, 2024 by Dow Jones
  4:05PM ET on Wednesday Nov 13, 2024 by Dow Jones
  Companies Mentioned: FDMT

Cartesian Therapeutics Inc
NASDAQ:RNACUnited States

Search Criteria

Nov 8, 2024

DJ Cartesian Therapeutics Is Maintained at Buy by HC Wainwright & Co., from 2:26PM ET on Friday Nov 08, 2024 by Dow Jones

Cartesian Therapeutics Announces New Employment Inducement Grants, from 7:05AM ET on Friday Nov 08, 2024 by Dow Jones

DJ Cartesian Therapeutics Price Target Maintained With a $41.00/Share by Needham, from 5:01AM ET on Friday Nov 08, 2024 by Dow Jones

Nov 7, 2024

-- Earnings Flash (RNAC) CARTESIAN THERAPEUTICS Posts Q3 Revenue $387,000, from 7:10AM ET on Thursday Nov 07, 2024 by MT Newswires

Press Release: Cartesian Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update, from 7:00AM ET on Thursday Nov 07, 2024 by Dow Jones

Peers Headlines

Yesterday

DJ Taysha Gene Therapies Is Maintained at Buy by Canaccord Genuity, from 23 hours ago by Dow Jones

Nov 14, 2024

DJ 4D Molecular Therapeutics Is Maintained at Buy by Chardan Capital, from 4:54PM ET on Thursday Nov 14, 2024 by Dow Jones

DJ Taysha Gene Therapies Price Target Maintained With a $6.00/Share by Needham, from 1:54PM ET on Thursday Nov 14, 2024 by Dow Jones

DJ 4D Molecular Therapeutics Price Target Maintained With a $36.00/Share by HC Wainwright & Co., from 1:41PM ET on Thursday Nov 14, 2024 by Dow Jones

DJ 4D Molecular Therapeutics Is Maintained at Outperform by RBC Capital, from 12:04PM ET on Thursday Nov 14, 2024 by Dow Jones

DJ Taysha Gene Therapies Price Target Maintained With a $7.00/Share by Cantor Fitzgerald, from 9:11AM ET on Thursday Nov 14, 2024 by Dow Jones

4DMT to Participate in Upcoming Investor Conferences and Ophthalmology Innovation Summit XIV, from 8:00AM ET on Thursday Nov 14, 2024 by Dow Jones

RBC Trims Price Target on 4D Molecular Therapeutics to $39 From $40, Keeps Outperform, Speculative Risk, from 6:59AM ET on Thursday Nov 14, 2024 by MT Newswires

Nov 13, 2024

-- Earnings Flash (TSHA) TAYSHA GENE THERAPIES Posts Q3 Revenue $1.79M, from 4:26PM ET on Wednesday Nov 13, 2024 by MT Newswires

4DMT Reports Third Quarter 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones, from 4:05PM ET on Wednesday Nov 13, 2024 by Dow Jones